Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Healthcare/Life Sciences
![The Political Turf Battle Over the Future of Your Prime Rib](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/The-Political-Turf-Battle-Over-the-Future-of-Your-Prime-400x400.jpeg)
The Political Turf Battle Over the Future of Your Prime Rib
- By nasdaqpicks.com
- . 3 August 2023
The White House must decide whether the Food and Drug Administration or Agriculture Department will oversee the food-company scientists tweaking genes to make animals heat
![AI-Generated Data Could Be a Boon for Healthcare—If Only It Seemed More Real](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/AI-Generated-Data-Could-Be-a-Boon-for-Healthcare—If-Only-It-400x400.jpeg)
AI-Generated Data Could Be a Boon for Healthcare—If Only It Seemed More Real
- By nasdaqpicks.com
- . 2 August 2023
What to Read Next Source link
![CVS Reports Stronger Demand](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/CVS-Reports-Stronger-Demand-400x400.jpeg)
CVS Reports Stronger Demand
- By nasdaqpicks.com
- . 2 August 2023
The healthcare company said a 10.3% increase in its second-quarter sales was driven by growth in its health benefits business. Source link
![Employers Cut Off Access to Weight-Loss Drugs for Workers](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Employers-Cut-Off-Access-to-Weight-Loss-Drugs-for-Workers-400x400.jpeg)
Employers Cut Off Access to Weight-Loss Drugs for Workers
- By nasdaqpicks.com
- . 2 August 2023
Costs are mounting for popular drugs such as Wegovy, a cousin of Ozempic, and healthcare plans are restricting coverage to save money. Source link
![Family of Henrietta Lacks, Whose Unique Cells Changed Science, Settles With Thermo Fisher](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Family-of-Henrietta-Lacks-Whose-Unique-Cells-Changed-Science-Settles-400x400.jpeg)
Family of Henrietta Lacks, Whose Unique Cells Changed Science, Settles With Thermo Fisher
- By nasdaqpicks.com
- . 1 August 2023
What to Read Next Source link
![Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Venture-Capitalist-Seeks-to-Spur-Drug-Development-for-Rare-Autoimmune-400x400.jpeg)
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
- By nasdaqpicks.com
- . 1 August 2023
Venture capitalist Luke Evnin has financed several successful biotechnology startups that develop treatments for cancer. Now he is encouraging drugmakers to tackle another disease: a rare autoimmune condition that
![Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Pfizer-Misses-Revenue-Expectations-Bets-on-Drug-Launches-to-Ease-400x400.jpeg)
Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall
- By nasdaqpicks.com
- . 1 August 2023
The company is rolling out 19 products or new uses within 18 months, CEO Albert Bourla said. Source link
![CVS to Shed 5,000 Jobs in Cost-Cutting Push](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/CVS-to-Shed-5000-Jobs-in-Cost-Cutting-Push-400x400.jpeg)
CVS to Shed 5,000 Jobs in Cost-Cutting Push
- By nasdaqpicks.com
- . 1 August 2023
The healthcare giant wants to trim corporate roles and spending on travel and its use of consultants. Source link
![Apple, Amazon, Starbucks to Report in Packed Earnings Week](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Apple-Amazon-Starbucks-to-Report-in-Packed-Earnings-Week-400x400.jpeg)
Apple, Amazon, Starbucks to Report in Packed Earnings Week
- By nasdaqpicks.com
- . 30 July 2023
Earnings reports also from Uber Technologies, Pfizer and Kraft Heinz are expected to shed light on how consumer spending is holding up amid rising interest
![Biogen to Buy Reata in $7.3 Billion Deal](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Biogen-to-Buy-Reata-in-73-Billion-Deal-400x400.jpeg)
Biogen to Buy Reata in $7.3 Billion Deal
- By nasdaqpicks.com
- . 28 July 2023
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link